Erika Newman was named the first associate director for diversity, equity, inclusion and justice at University of Michigan Rogel Cancer Center.
Luisa Iruela-Arispe, a vascular biologist, was named co-leader of the Tumor Environment and Metastasis Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Navneet Majhail was named deputy physician-in-chief of blood cancers for the Sarah Cannon Transplant and Cellular Therapy Network (formerly the Sarah Cannon Blood Cancer Network).
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, in partnership with the New Brunswick Development Corporation, broke ground on the state’s first freestanding cancer hospital.
University of California, San Francisco has established a initiative to propel the development of living therapeutics and bring them quickly to patients.
COTA, an oncology real-world data and analytics company, and University of Chicago Medicine have established a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
A group of cancer centers is collaborating with Genentech on a clinical trial diversity, launching the Advancing Inclusive Research Site Alliance.
In a joint position statement, the American Society of Clinical Oncology and Friends of Cancer Research said individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion.
A study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein.
In children with rhabdomyosarcoma, a rare cancer that affects the muscles and other soft tissues, the presence of mutations in several genes, including TP53, MYOD1, and CDKN2A, appears to be associated with a more aggressive form of the disease and a poorer chance of survival.
